Abstract
Fludarabine is one of the most recent and promising therapeutic agents for chronic lymphocytic leukaemia. We describe a patient who developed tumour lysis syndrome after the first course of treatment with fludarabine and call attention to this uncommon but potentially lethal complication that has not been previously taken into account in this neoplasia. It should always be anticipated when patients are treated with new and effective drugs.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bergmann L., Fenchel K., Jahn B., Mitrou P. S., Hoelzer D. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol. 1993 May;4(5):371–375. doi: 10.1093/oxfordjournals.annonc.a058515. [DOI] [PubMed] [Google Scholar]
- Elias L., Stock-Novack D., Head D. R., Grever M. R., Weick J. K., Chapman R. A., Godwin J. E., Metz E. N., Appelbaum F. R. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. Leukemia. 1993 Mar;7(3):361–365. [PubMed] [Google Scholar]
- Frame J. N., Dahut W. L., Crowley S. Fludarabine and acute tumor lysis in chronic lymphocytic leukemia. N Engl J Med. 1992 Nov 5;327(19):1396–1397. doi: 10.1056/NEJM199211053271921. [DOI] [PubMed] [Google Scholar]
- Gomez G. A., Han T. Acute tumor lysis syndrome in prolymphocytic leukemia. Arch Intern Med. 1987 Feb;147(2):375–376. [PubMed] [Google Scholar]
- Keating M. J., Kantarjian H., O'Brien S., Koller C., Talpaz M., Schachner J., Childs C. C., Freireich E. J., McCredie K. B. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol. 1991 Jan;9(1):44–49. doi: 10.1200/JCO.1991.9.1.44. [DOI] [PubMed] [Google Scholar]
- Keating M. J., Kantarjian H., Talpaz M., Redman J., Koller C., Barlogie B., Velasquez W., Plunkett W., Freireich E. J., McCredie K. B. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989 Jul;74(1):19–25. [PubMed] [Google Scholar]
- List A. F., Kummet T. D., Adams J. D., Chun H. G. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am J Med. 1990 Sep;89(3):388–390. doi: 10.1016/0002-9343(90)90358-k. [DOI] [PubMed] [Google Scholar]
- McCroskey R. D., Mosher D. F., Spencer C. D., Prendergast E., Longo W. L. Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. Cancer. 1990 Jul 15;66(2):246–250. doi: 10.1002/1097-0142(19900715)66:2<246::aid-cncr2820660209>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
- Redman J. R., Cabanillas F., Velasquez W. S., McLaughlin P., Hagemeister F. B., Swan F., Jr, Rodriguez M. A., Plunkett W. K., Keating M. J. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992 May;10(5):790–794. doi: 10.1200/JCO.1992.10.5.790. [DOI] [PubMed] [Google Scholar]
- Ross S. R., McTavish D., Faulds D. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. Drugs. 1993 May;45(5):737–759. doi: 10.2165/00003495-199345050-00009. [DOI] [PubMed] [Google Scholar]